Literature DB >> 2138673

CD8+ T lymphocyte subset in giant cell arteritis and related disorders.

P Elling1, A Olsson, H Elling.   

Abstract

Median percentage and number of circulating CD8+ T lymphocytes (suppressor/cytotoxic T lymphocytes) are markedly decreased in patients with giant cell arteritis (GCA). We assessed the diagnostic usefulness of CD8+ T cell values, in 108 patients who had a temporal artery biopsy during a 3 year period. Histologic evidence of GCA was found in 26 patients. Negative biopsy patients were divided into 2 groups, one with 49 patients and a probable GCA syndrome (polymyalgia rheumatica with a negative biopsy) and a group with non-GCA (33 patients). Median percentage and number of CD8+ T cells were significantly decreased with definite GCA (CD8+% 10.0, CD8+ cells 0.221 x 10(9)/l), and probable GCA syndrome (CD8+% 10.0, CD8+ cells 0.197 x 10(9)/l) compared with non-GCA (CD8+% 22.0, CD8+ cells 0.527 x 10(9)/l) and controls (CD8% 21, CD8+ cells 0.518 x 10(9)/l). Significantly low CD8+ T cell values were found in nearly 80% of patients with active untreated GCA or GCA syndrome and in 15% of patients with non-GCA. Positive predictive value of a significant low CD8+ T cell value is 85% while the likelihood of no GCA or GCA syndrome with normal CD8+ T cell values is 60%.

Entities:  

Mesh:

Year:  1990        PMID: 2138673

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  9 in total

1.  Peripheral blood lymphocyte subsets in polymyalgia rheumatica.

Authors:  A Uddhammar; G Roos; B Näsman; S R Dahlqvist
Journal:  Clin Rheumatol       Date:  1995-01       Impact factor: 2.980

2.  Circulating T cell subtypes in polymyalgia rheumatica and giant cell arteritis: variation in the percentage of CD8+ cells with prednisolone treatment.

Authors:  G S Panayi
Journal:  Ann Rheum Dis       Date:  1994-04       Impact factor: 19.103

3.  Circulating T cell subtypes in polymyalgia rheumatica and giant cell arteritis: variation in the percentage of CD8+ cells with prednisolone treatment.

Authors:  G D Pountain; M T Keogan; D L Brown; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1993-10       Impact factor: 19.103

4.  The Cambridge dilemma.

Authors:  P Elling; H Elling; A T Olsson
Journal:  Ann Rheum Dis       Date:  1994-11       Impact factor: 19.103

Review 5.  Pro-inflammatory and anti-inflammatory T cells in giant cell arteritis.

Authors:  Ryu Watanabe; Ebru Hosgur; Hui Zhang; Zhenke Wen; Gerald Berry; Jörg J Goronzy; Cornelia M Weyand
Journal:  Joint Bone Spine       Date:  2016-09-20       Impact factor: 4.929

6.  Treatment of polymyalgia rheumatica with intramuscular injections of depot methylprednisolone.

Authors:  B Dasgupta; J Gray; L Fernandes; C Olliff
Journal:  Ann Rheum Dis       Date:  1991-12       Impact factor: 19.103

7.  Role of peripheral CD8 lymphocytes and soluble IL-2 receptor in predicting the duration of corticosteroid treatment in polymyalgia rheumatica and giant cell arteritis.

Authors:  C Salvarani; L Boiardi; P Macchioni; F Rossi; P Tartoni; M Casadei Maldini; R Mancini; E Beltrandi; I Portioli
Journal:  Ann Rheum Dis       Date:  1995-08       Impact factor: 19.103

Review 8.  Cellular Signaling Pathways in Medium and Large Vessel Vasculitis.

Authors:  Ryu Watanabe; Gerald J Berry; David H Liang; Jörg J Goronzy; Cornelia M Weyand
Journal:  Front Immunol       Date:  2020-09-25       Impact factor: 7.561

Review 9.  Innate and Adaptive Immunity in Giant Cell Arteritis.

Authors:  Mitsuhiro Akiyama; Shozo Ohtsuki; Gerald J Berry; David H Liang; Jörg J Goronzy; Cornelia M Weyand
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.